New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phneylpiperazine dopaminergic template

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 19, 1998, Pages 2675-2680

  Mewshaw, Richard E ^a   Verwijs, Antoine ^a   Shi, Xiaojie ^a   McGaughey, Georgia B ^a   Nelson, James A ^a   Mazandarani, Hossein ^a   Brennan, Julie A ^a   Marquis, Karen L ^a   Coupet, Joseph ^a   Andree, Terrance H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PIPERAZINE DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; DRUG CONFORMATION; DRUG SYNTHESIS; MOLECULAR MODEL;

ANIMALS; BENZIMIDAZOLES; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AGONISTS; INDOLES; KINETICS; PIPERAZINES; PSYCHOTROPIC DRUGS; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPLATES, GENETIC;

EID: 0032491240     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00474-0     Document Type: Article

References (14)

1. 1. Kaiser, C.; Jain, T. Med Res. Rev. 1985, 5, 145.
2. 2. Seyfried, C. A.; Boettcher, H. Drugs Future 1990, 15, 819.
3. 3. Wikstrom, H. Prog. in Med. Chem. 1992, 29, 185.
4. 4. Wikstrom, H.; Sanchez, D.; Lindberg, P.; Arvidsson, L. E.; Hacksell, U.; Johansson, A., Nilsson, J. L. G.; Hjorth, S.; Carlsson, A. J. Med. Chem. 1989, 25, 925.
5. 5. For Part 4, see Mewshaw, R. E.; Marquis K. L.; Shi, X., McGaughey, G.; Stack, G.; Webb, M. B.; Abou-Gharbia, M., Wasik, T.; Scerni, R.; Spangler, T.; Brennan, J. A.; Mazandarani, H.; Coupet, J.; Andree, T. H. Tetrahedron, 1998, 54, 7081 and references therein.
6. 6. Mewshaw, R. E.; Husbands, M.; Gildersleeve, E. S.; Webb, M. B.; Shi, X.; Mazandarani, H.; Cockett, M. I.; Ochalski, R.; Brennan, J. A.; Abou-Gharbia, M.; Marquis, K.; McGaughey, G. B.; Coupet, J.; Andree, T. H. Bioorg. Med. Chem. Lett. 1998, 8, 295.
7. 7. Gassman, P. G.; van Bergen, T. J. J. Am. Chem. Soc. 1974, 96, 5508.
8. 8. Toyota, M.; Fukumoto, K. J. Chem. Soc. Perkin Trans. 1 1992, 5, 547.
9. 9. Lahti, R. A.; Figur, L. M.; Peircey, M. F.; Ruppel, P. L.; Evans, D. L. Mol. Pharm. 1992, 42, 432.
10. 10. Wasik, T.; Cockett, M.; Andree, T. H. Soc. Neurosci. Abst. 1996, 22: 831.
11. 11. Mewshaw, R. E.; Kavanagh, J.; Stack, G.; Marquis, K.; Shi, X.; Kagan, M. Z.; Webb, M. B.; Katz, A. H.; Park, A.; Kang, Y. H.; Abou-Gharbia, M.; Wasik, T.; Cortes-Burgos, L.; Scerni, R.; Spangler, T.; Brennan, J. A.; Piesla, M.; Mazandarani, H.; Coupet, J.; Andree, T. H. J. Med. Chem. 1997, 40, 4235.
12. i values are the means of n = 2-3 experiments run at six different concentrations. Each experiment was carried out in triplicate. 95% confidence limits were generally ± 15% of the mean value.
13. 13. All computations were performed using MM3 as implemented in Macromodel 6.0.
14. 14. McDermed, J. D.; Freeman, H. S. Catecholamines: Basic and Clinical Frontiers; Usdin, E.; Kopin, I; Barchas, J., Eds.; Pergamon: New York, 1979; Vol. 1, p 568.